Dr. Kim takes over for Michael Sumner, MD, who has been in the role since 2013, according to an Oct. 26 press release.
Dr. Kim will be located at the company’s U.S. subsidiary in Morristown, N.J., and will lead the U.S. medical affairs department.
He will also work closely with the pharmaceutical team in Sweden on the development of Orexo’s AmorphOX platform, which focuses on innovative treatments for patients with substance abuse disorders.
Prior to his new role, Dr. Kim worked as a psychiatrist for 13 years before joining Biohaven Pharmaceuticals as its vice president and head of medical affairs.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
